Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/09/2000WO2000066093A2 Combined preparations comprising morpholine anthracyclines and anticancer agent
11/09/2000WO2000066090A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000066082A1 Anti-nausea compositions and methods
11/09/2000WO2000066068A2 Method for inducing growth and enhancing survival of nervous tissue
11/09/2000WO2000066067A2 Ibd-associated microbial antigens and methods of using same
11/09/2000WO2000041504A3 Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
11/09/2000WO2000041463A3 Combination of hepatitis b vaccine with antiviral agents
11/09/2000WO2000040235A3 Treatment of asthma with mek inhibitors
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000038661A3 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
11/09/2000WO2000037489A3 Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same
11/09/2000WO2000035437A3 Improving mental performance by increasing brain insulin sensitivity
11/09/2000WO2000034477A3 Neuron-associated proteins
11/09/2000WO2000033790A3 Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
11/09/2000WO2000032624A3 Uncoupling protein 5 - ucp5
11/09/2000WO2000031238A3 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
11/09/2000WO2000031123A3 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
11/09/2000WO2000030671A3 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
11/09/2000WO2000028981A3 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
11/09/2000WO2000028034A3 Cytokine signal regulators
11/09/2000WO2000027422A3 Methods and compositions for treating or preventing peripheral neuropathies
11/09/2000WO2000024780A3 Compositions and methods for treating polycystic kidney disease
11/09/2000WO2000024771A3 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
11/09/2000WO2000021996A3 Methods and compositions for inhibiting neoplastic cell growth
11/09/2000WO2000021509A3 Methods of treatment
11/09/2000WO2000015826A3 Leptin induced genes
11/09/2000WO2000006737A8 Streptococcus pneumoniae proteins and nucleic acid molecules
11/09/2000WO2000004050A3 Neurotrophic growth factor
11/09/2000WO2000001349A3 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
11/09/2000WO1999056769A3 Inhibition of helicobacter pylori proliferation
11/09/2000WO1999055868A3 Fizz proteins
11/09/2000WO1999045907A9 Metal chelators for use in the treatment of alzheimer's disease
11/09/2000DE19922443A1 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen Use of dopamine D3 receptor ligands for the preparation of drugs for the treatment of renal dysfunction
11/09/2000CA2372947A1 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372834A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles
11/09/2000CA2372803A1 Variants of traf2 which act as an inhibitor of tnf-alpha (tnf .alpha.) signaling pathway
11/09/2000CA2372773A1 Contraceptive compositions containing antiprogestinic and progestinic
11/09/2000CA2372768A1 Contraceptive compositions containing cyclic urea and amide derivatives
11/09/2000CA2372595A1 Contraceptive compositions containing indoline derivatives and progestational agents
11/09/2000CA2372591A1 Contraceptive compositions containing 3,3-substituted indoline derivatives and uses thereof
11/09/2000CA2372586A1 Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestationals
11/09/2000CA2372279A1 Compositions containing benzimidazolones and progestogens
11/09/2000CA2372225A1 Anti-nausea compositions and methods
11/09/2000CA2372223A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000CA2372220A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000CA2372214A1 Modified exendins and exendin agonists
11/09/2000CA2372190A1 Methods for the treatment of neuronal atrophy-associated dementia
11/09/2000CA2372073A1 Glycine cleavage system inhibitors as potential antipsychotics
11/09/2000CA2371757A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000CA2371604A1 Integrin receptor antagonists
11/09/2000CA2371596A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
11/09/2000CA2371421A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000CA2371260A1 Materials and methods relating to neuronal development
11/09/2000CA2371215A1 New compounds
11/09/2000CA2370821A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000CA2370587A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000CA2370177A1 Methods for the identification of compounds for the treatment of alzheimer's disease
11/09/2000CA2370119A1 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
11/09/2000CA2370111A1 Optical probes and assays
11/09/2000CA2369550A1 Methods and formulations for targeting infectious agents bearing host cell proteins
11/09/2000CA2369526A1 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000CA2369371A1 Death domain containing receptor 5
11/09/2000CA2369077A1 Contraceptive compositions containing quinazolinone and benzoxazine derivatives
11/09/2000CA2368801A1 Conjugates as therapies for cancer and prostate diseases
11/09/2000CA2368779A1 Contraceptive compositions containing cyclic carbamates and amide derivatives
11/09/2000CA2368748A1 X-ray guided drug delivery
11/09/2000CA2365900A1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000CA2365776A1 Method for treating abnormal cell proliferation in the brain
11/09/2000CA2335966A1 Method for inducing growth and enhancing survival of nervous tissue
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/08/2000EP1050303A2 Methods and compositions for treating age-related behavioral disorders in companion animals
11/08/2000EP1050298A2 Composition for treating and/or ameliorating the diseases of dandruff, seborrheic dermatitis, psoriasis and eczema and symptoms thereof
11/08/2000EP1049796A1 Methods for the simultaneous identification of novel biological targets and lead structures for drug development
11/08/2000EP1049780A1 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/08/2000EP1049775A1 Human btrcp protein
11/08/2000EP1049774A2 Promoter regions of the mouse and human telomerase rna component genes
11/08/2000EP1049490A2 Method for inhibiting cd95-independent apoptosis in aids
11/08/2000EP1049483A1 Method for treating inflammatory diseases using heat shock proteins
11/08/2000EP1049478A1 Composition containing propargylamine for enhancing cancer therapy
11/08/2000EP1049471A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
11/08/2000EP1049465A1 Use of inhibitors for the treatment of disorders related to rtk hyperfunction, especially cancer
11/08/2000EP1049464A2 Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
11/08/2000EP1049462A1 Choline esters of fatty acids and their use in the treatment of stroke
11/08/2000EP1049459A1 Oral liquid compositions
11/08/2000EP1049457A1 Bioactive glass treatment of inflammation in skin conditions
11/08/2000EP0769006B1 Small molecule inhibitors of rotamase enzyme activity
11/08/2000CN1272884A Adipocyte-specific protein homologs
11/08/2000CN1272793A Method of protecting against chronic infections
11/08/2000CN1272789A Pharmaceutical compositions for oral administration of molecular iodine
11/08/2000CN1272788A Method for treating psychosis associated with glucocorticoid related dysfunction
11/08/2000CN1272786A Endothelin antagonist and beta receptor blocking agent as combined preparation
11/08/2000CN1272784A Medicinal compositions for application to mucosa
11/08/2000CN1058150C Topical aromatic releasing compositions
11/07/2000US6143867 Amino acid sequence; for diagnosis, prevention, and treatment of late-phase allergic/inflammatory reactions, eosinophilias, parasitic infections, conditions associated with placental derived-basic protein accumulation in pregnancy
11/07/2000US6143782 Anti-inflammatory and anti-asthma treatment with reduced side effects
11/07/2000US6143755 Pharmaceutical methods of treatment with ACAT inhibitors and HMG-CoA reductase inhibitors
11/07/2000US6143746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
11/07/2000US6143742 Treatment for necrotizing infections
1 ... 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 ... 1151